Literature DB >> 18580585

Revising the ADAS-cog for a more accurate assessment of cognitive impairment.

Hans Wouters1, Willem A van Gool, Ben Schmand, Robert Lindeboom.   

Abstract

BACKGROUND: To examine whether it is appropriate to sum the cognitive part of the Alzheimer Disease Assessment Scale (ADAS-cog) items to assess cognitive impairment. This assumes items to have (1) equal measurement precision and (2) hierarchically ordered categories.
METHODS: Rasch analysis on the basis of pooled data from 3 Randomized Controlled Trials was used to examine these assumptions and to estimate each patient's level of impairment. Analyses were replicated in an independent sample.
RESULTS: The original ADAS-cog scoring did not fit the Rasch Model and did not reliably distinguish between impairment levels. Patients with equal test scores had different impairment levels. Similarly, patients with different test scores could have the same impairment level. Revising the ADAS-cog by (1) weighting the items by their measurement precision and (2) collapsing nonhierarchical item categories resulted in good fit and a valid one to one correspondence between sum scores and estimated impairment levels. This revealed that equal differences in ADAS-cog scores did not reflect equal differences in impairment level along the test's score range.
CONCLUSIONS: It is appropriate to summate the ADAS-cog items provided that the items are weighted and have their categories hierarchically ordered.

Entities:  

Mesh:

Year:  2008        PMID: 18580585     DOI: 10.1097/WAD.0b013e318174f8b9

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  9 in total

1.  Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

2.  The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.

Authors:  Jeannine Skinner; Janessa O Carvalho; Guy G Potter; April Thames; Elizabeth Zelinski; Paul K Crane; Laura E Gibbons
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

3.  Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease.

Authors:  Edna Grünblatt; Sonja Zehetmayer; Christian P Jacob; Thomas Müller; Wolfgang H Jost; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2010-11-11       Impact factor: 3.575

4.  Psychometric properties of Addenbrooke's Cognitive Examination III (ACE-III): An item response theory approach.

Authors:  Carlos Calderón; Christian Beyle; Oscar Véliz-García; Juan Bekios-Calfa
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

Review 5.  Item response theory analysis of cognitive tests in people with dementia: a systematic review.

Authors:  Sarah McGrory; Jason M Doherty; Elizabeth J Austin; John M Starr; Susan D Shenkin
Journal:  BMC Psychiatry       Date:  2014-02-19       Impact factor: 3.630

Review 6.  The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.

Authors:  Jacqueline K Kueper; Mark Speechley; Manuel Montero-Odasso
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Measuring global functioning in older adults with cognitive impairments using the Rasch model.

Authors:  Rocco Palumbo; Alberto Di Domenico; Federica Piras; Salvatore Bazzano; Mario Zerilli; Fabio Lorico; Erika Borella
Journal:  BMC Geriatr       Date:  2020-11-23       Impact factor: 3.921

Review 8.  Item Response Theory Analysis of the Fear of COVID-19 Scale (FCV-19S): A Systematic Review.

Authors:  Zainab Alimoradi; Chung-Ying Lin; Irfan Ullah; Mark D Griffiths; Amir H Pakpour
Journal:  Psychol Res Behav Manag       Date:  2022-03-08

Review 9.  FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry".

Authors:  Marwan N Sabbagh; Suzanne Hendrix; John E Harrison
Journal:  Alzheimers Dement (N Y)       Date:  2019-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.